Sign In
Buy ZEPP
Zepp Health Earnings Calls
| Release date | Jun 08, 2026 |
| EPS estimate | - |
| EPS actual | -$1.13 |
| Revenue estimate | - |
| Revenue actual | 38.537M |
| Release date | Mar 15, 2026 |
| EPS estimate | - |
| EPS actual | -$0.400 |
| Revenue estimate | - |
| Revenue actual | 85.165M |
| Release date | Nov 04, 2025 |
| EPS estimate | - |
| EPS actual | -$0.0400 |
| Revenue estimate | - |
| Revenue actual | 75.782M |
| Release date | Aug 03, 2025 |
| EPS estimate | - |
| EPS actual | -$0.390 |
| Revenue estimate | - |
| Revenue actual | 59.556M |
Last 4 Quarters for Zepp Health
Below you can see how ZEPP performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 03, 2025 |
| Price on release | $13.00 |
| EPS estimate | - |
| EPS actual | -$0.390 |
| Date | Price |
|---|---|
| Jul 28, 2025 | $13.73 |
| Jul 29, 2025 | $12.57 |
| Jul 30, 2025 | $12.10 |
| Jul 31, 2025 | $13.46 |
| Aug 01, 2025 | $13.00 |
| Aug 04, 2025 | $17.42 |
| Aug 05, 2025 | $24.06 |
| Aug 06, 2025 | $25.33 |
| Aug 07, 2025 | $24.30 |
| 4 days before | -5.32% |
| 4 days after | 86.92% |
| On release day | 34.00% |
| Change in period | 76.98% |
| Release date | Nov 04, 2025 |
| Price on release | $37.07 |
| EPS estimate | - |
| EPS actual | -$0.0400 |
| Date | Price |
|---|---|
| Oct 29, 2025 | $40.10 |
| Oct 30, 2025 | $39.40 |
| Oct 31, 2025 | $40.38 |
| Nov 03, 2025 | $38.90 |
| Nov 04, 2025 | $37.07 |
| Nov 05, 2025 | $35.47 |
| Nov 06, 2025 | $27.73 |
| Nov 07, 2025 | $27.29 |
| Nov 10, 2025 | $22.33 |
| 4 days before | -7.56% |
| 4 days after | -39.76% |
| On release day | -4.32% |
| Change in period | -44.31% |
| Release date | Mar 15, 2026 |
| Price on release | $20.83 |
| EPS estimate | - |
| EPS actual | -$0.400 |
| Date | Price |
|---|---|
| Mar 09, 2026 | $18.74 |
| Mar 10, 2026 | $20.10 |
| Mar 11, 2026 | $20.77 |
| Mar 12, 2026 | $20.59 |
| Mar 13, 2026 | $20.83 |
| Mar 16, 2026 | $16.22 |
| Mar 17, 2026 | $15.17 |
| Mar 18, 2026 | $14.82 |
| Mar 19, 2026 | $14.01 |
| 4 days before | 11.15% |
| 4 days after | -32.74% |
| On release day | -22.13% |
| Change in period | -25.24% |
| Release date | Jun 08, 2026 |
| Price on release | $6.18 |
| EPS estimate | - |
| EPS actual | -$1.13 |
| Date | Price |
|---|---|
| Jun 02, 2026 | $7.60 |
| Jun 03, 2026 | $6.80 |
| Jun 04, 2026 | $6.46 |
| Jun 05, 2026 | $6.19 |
| Jun 08, 2026 | $6.18 |
| Jun 09, 2026 | $4.41 |
| Jun 10, 2026 | $3.99 |
| Jun 11, 2026 | $4.77 |
| Jun 12, 2026 | $4.69 |
| 4 days before | -18.68% |
| 4 days after | -24.11% |
| On release day | -28.64% |
| Change in period | -38.29% |
Zepp Health Earnings Call Transcript Summary of Q1 2026
Q1 2026 highlights: Revenue $51.5M, up 33.8% year-over-year, driven by strong Amazfit brand performance and multiple new product launches (Amazfit Active Max, Active 3 Premium, T‑Rex Ultra 2, Balance series, Cheetah 2). Average selling price rose >20% year-over-year, supporting gross margin expansion to 37.7% (up 0.4 pts YoY) despite higher memory costs and FX headwinds. Operating loss narrowed to $6.3M; adjusted net loss $17.9M. Cash and equivalents $103.2M; inventory reduced to $62.8M. Management reiterated strategic shift toward premiumization and building a "hybrid training" platform (hardware + AI/software + partnerships), signing an exclusive 3‑year global partnership with HYROX to deepen presence in hybrid endurance communities. Q2 2026 guidance: revenue $63M–$68M (≈6%–14% YoY). Key risks and near‑term headwinds include rising memory costs (DDR5 transition), unfavorable FX, and front‑loaded marketing/R&D spend; management says they have mitigants (pricing power, sourcing, cost discipline). Capital actions: $17M repurchased under $20M buyback program to date; debt broadly stable.
